Our own worst enemy: Pharmacologic mechanisms of hypertension

Advances in Chronic Kidney Disease

Volumn 22, Issue 3, 2015, Pages 245-252

  Kassel, Lynn E ^a   Odum, Lauren E ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Blood pressure; Drug induced; Hypertension; Resistant hypertension; Secondary hypertension

Indexed keywords

ALKALOID DERIVATIVE; AMPHETAMINE DERIVATIVE; ANTIANEMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; CENTRAL STIMULANT AGENT; COCAINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ERGOT ALKALOID; ESTROGEN; KETAMINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLEPHRINE; PSEUDOEPHEDRINE; TESTOSTERONE; VASCULOTROPIN INHIBITOR; YOHIMBINE; ANGIOGENESIS INHIBITOR; ORAL CONTRACEPTIVE AGENT;

DRUG ANTAGONISM; DRUG MECHANISM; GLYCYRRHIZA; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; CHEMICALLY INDUCED; ESTROGEN THERAPY;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CALCINEURIN INHIBITORS; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; HEMATINICS; HUMANS; HYPERTENSION;

EID: 84928005079     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.10.002     Document Type: Review

References (89)

1. Sager P., Heilbraun J., Turner J.R., et al. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J 2013, 165(4):477-488.
2. Blankfield R.P., Iftikhar I.H. Food and Drug Administration regulation of drugs that raise blood pressure. J Cardiovasc Pharmacol Ther 2014, 20(1):5-8.
3. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51(6):1403-1419.
4. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
5. Rossi G.P., Seccia T.M., Maniero C., Pessina A.C. Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J Hypertens 2011, 29(12):2295-2309.
6. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121(4):289-300.
7. Treadwell B.L., Sever E.D., Savage O., et al. Side-effects of long-termtreatment with corticosteroids and corticotrophin. Lancet 1964, 1(7343):1121-1123.
8. Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012, 124(1):14-22.
9. Connell J.M., Whitworth J.A., Davies D.L., et al. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987, 5(4):425-433.
10. Montrella-Wabill M., Clore J.N., Schoolwerth A.C., et al. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991, 72(5):1060-1066.
11. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996, 14(5):S37-S41.
12. Ong S.L.H., Whitworth J.A. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am 2011, 40(2):393-407.
13. Goodwin J.E., Gellar D.S. Glucocorticoid-induced hypertension. Pediatr Nephrol 2012, 27(7):1059-1066.
14. Stewart P.M., Wallace A.M., Valentino R., et al. Mineralocorticoid actions of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 23(2):821-824.
15. Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab 2003, 17(4):575-589.
16. Sundoul E., Kaeser J. Correction of anemia of chronic renal failurewith recombinant erythropoietin: safety and efficacy at one year's treatment in a European multicenter study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 1989, 4(11):979-987.
17. Morakkabati N., Gollnick F., Meyer R., Fandrey J., Jelkmann W. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996, 24(2):392-397.
18. Vaziri N.D. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999, 33(5):821-828.
19. Procrit [package insert] 2013, Amgen Inc., Thousand Oaks, CA.
20. Aranesp [package insert] 2013, Amgen Inc., Thousand Oaks, CA.
21. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. Accessed June2014.
22. Robert N., Wong G.W.K., Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010, (1):CD007893.
23. Hoorn E.J., Walsh S.B., McCormick J.A., Zietse R., Unwin R.J., Ellison D.H. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012, 25(3):269-275.
24. Curtis J.J., Luke R.G., Jones P., Diethelm A.G. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988, 85(2):134-138.
25. Perico N., Dadan J., Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990, 1(1):76-83.
26. Artz M.A., Boots J.M., Ligtenberg G., et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003, 14(7):1880-1888.
27. Artz M.A., Boots J.M., Ligtenberg G., et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004, 4(6):937-945.
28. Cifkova R., Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001, 19(12):2283-2285.
29. Roose S.P., Dalack G.W., Glassman A.H., et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991, 148(4):512-516.
30. Zyban [package insert] 2008, GlaxoSmithKline, Greenville, NC.
31. Wellbutrin XL [package insert] 2008, GlaxoSmithKline, Research Triangle, NC.
32. Clyburn E.B., DiPette D.J. Hypertension induced by drugs and other substances. Semin Nephrol 1995, 15(2):72-86.
33. Fallon B., Foote B., Walsh B.T., Roose S.P. 'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry 1998, 49(4):163-165.
34. Gunn J., Hamilton M.M., Boyle R.M. Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor. BMJ 1987, 298(6698):964.
35. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998, 59(10):502-508.
36. Pristiq [package insert] 2009, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
37. Feighner J.P. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999, 60(suppl 14):4-11.
38. Grossman E., Messerli F.H. Secondary hypertension: interfering substances. J Clin Hypertens 2008, 10(7):556-566.
39. Nzerue C.M., Hewan-Lowe K., Riley L.J. Cocaine and the kidney: a synthesis of pathophysiologic and clinical and perspectives. Am J Kidney Dis 2000, 35(5):783-795.
40. Samuels J.A., Franco K., Wan F., Sorof J.M. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006, 21(1):92-95.
41. Rutstein H.R. Hypertension and unconsciousness following: report of a case, ingestion of pseudoephedrine. Arch Otolaryngol 1963, 77:145-147.
42. Chua S.S., Benrimoj S.I., Gordon R.D., Williams G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. Br J Clin Pharmacol 1989, 28(3):369-372.
43. Bradley J.G., Kallail K.J., Dorsch J.N., Fox J. The effect of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial. J Am Board Fam Pract 1991, 4(4):201-206.
44. Coates M.L., Rembold C.M., Farr B.M. Does pseudoephedrine increase blood pressure in patients with controlled hypertension?. J Fam Pract 1995, 40(1):22-26.
45. Salerno S.M., Jackson J.L., Berbano E.P. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med 2005, 165(15):1686-1694.
46. Lai Y.K. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol 1989, 73(6):468-469.
47. Fraunfelder F.W., Fraunfelder F.T., Jensvold B. Adverse systemic effects from pledgets of topical ocular phenylephrine 10%. Am J Ophthalmol 2002, 134(4):624-625.
48. Haller C.A., Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343(25):1833-1838.
49. Samenuk D., Link M.S., Homoud M.K., et al. Cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002, 77(1):12-16.
50. Jalili J., Askeroglu U., Alleyne B., Guyuron B. herbal products that maycontribute to hypertension. Plast Reconstr Surg 2013, 131(1):168-173.
51. FDA. FDA acts to remove ephedra-containing dietary supplements frommarket. P04-P106; 2004. Available at: . Accessed July 15, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108379.htm.
52. Inchiosa M.A. Experience (mostly negative) with the use of sympathomimetic agents for weight loss. J Obes 2011, [e-pub 2010 Aug 12].
53. Therapeutic Research Faculty. Yohimbe. Medline Plus, a service of the US National Library of Medicine, National Institutes of Health. Available at: . Accessed July 11, 2014. http://www.nlm.nih.gov/medlineplus/druginfo/natural/759.html.
54. Kaminski P., Szpotanska-Sikorska M., Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuroendocrinol Lett 2013, 34(7):585-589.
55. Cagnacci A., Ferrari S., Napolitano A., et al. Combined oral contraceptive containing drosperinone does not modify 24-hr ambulatory blood pressure but increases heart rate in healthy young women: prospective study. Contraception 2013, 88(3):413-417.
56. Laragh J.H., Sealey J.E., Ledingham J.G.G., Newton M.A. Oral contraceptives, renin, aldosterone, and high blood pressure. JAMA 1967, 201(12):98-102.
57. Goldhaber S.Z., Hennekens C.H., Spark R.F., et al. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J 1984, 107(1):119-122.
58. Boldo A., White W.B. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin N Am 2011, 40(2):419-432.
59. Gourdy P., Bachelot A., Catteau-Jonard S., et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol 2012, 73(5):469-487.
60. Brito M.B., Nobre F., Vieira C.S. Hormonal contraception and cardiovascular system. Arq Bras Cardiol 2011, 96(4):e81-e89.
61. Shufelt C.L., Merz C.N.B. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009, 53(3):221-231.
62. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 73. American College of Obstetrics and Gynecologists. Obstet Gynecol 2006, 107(6):1453-1472. American College of Obstetrics and Gynecology.
63. Steenland M.W., Zapata L.B., Brahmi D., Marchbanks P.A., Curtis K.M. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013, 87(5):611-624.
64. Park H., Kim K. Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women. BMC Womens Health 2013, 13(39):1-7.
65. Rossouw J.E. Effect of postmenopausal hormone therapy on cardiovascular risk. J Hypertens 2002, 20(suppl 2):S62-S65.
66. Androderm [package insert] 2013, Watson Pharm, Inc., Parsippany, NJ.
67. Androgel [package insert] 2013, AbbVie Inc., North Chicago, IL.
68. Tangredi J.F., Buxton I.L.O. Hypertension as a complication of topicaltestosterone therapy. Ann Pharmacother 2001, 35(10):1205-1207.
69. Ziemens B., Wallaschofski H., Volzke H., et al. Positive association between testosterone, blood pressure, and hypertension in women: longitudinal findings from the Study of Health in Pomerania. J Hypertens 2013, 31(6):1106-1113.
70. Gyamlani G., Geraci S.A. Secondary hypertension due to drugs and toxins. South Med J 2007, 100(7):692-699.
71. Kruzliak P., Kovacova G., Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis 2013, 16(2):289-295.
72. Kruzliak P., Novak J., Novak M. Vascular endothelial growth factorinhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens 2014, 27(1):3-13.
73. Rosiak J., Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs 2005, 9(4):407-411.
74. Sunshine S.B., Dallabrida S.M., Durand E., et al. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 2012, 109(28):11306-11311.
75. Maitland M.L., Kasza K.E., Karrison T., et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009, 15(19):6250-6257.
76. Langenberg M.H., van Herpen C.M., De Bono J., et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase ii randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009, 27(36):6152-6159.
77. Humphreys B.D., Atkins M.B. Rapid development of hypertension by sorafenib: toxicity or target?. Clin Cancer Res 2009, 15(19):5947-5949.
78. Escalante C.P., Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011, 2011:816897. epub 2001 may 10.
79. Robinson E.S., Matulonis U.A., Ivy P., et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010, 5(3):477-483.
80. Saseen J.J. Hypertension. Drug Induced Diseases: Prevention, Detection, and Management 2010, 516-528. American Society of Health-System Pharmacists, Inc., Bethesda, MD. J.E. Tisdale, D.A. Miller (Eds.).
81. Kappers M.H.W., van Esch J.H.M., Sluiter W., et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010, 56(4):675-681.
82. Copur M.S., Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011, 10(3):151-156.
83. Nagasawa T., Khan M.A.H., Imig J.D. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol 2012, 39(5):454-461.
84. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49(2):186-193.
85. McCord J., Jneid H., Hollander J.E., et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council of Clinical Cardiology. Circulation 2008, 117(14):1897-1907.
86. Miyashita K., Tojo A., Kimura K., et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004, 27(2):79-84.
87. Nisenbaum M.G., de Malo N.R., Galvao Giribela C.R., et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014, 175:62-66.
88. Cannoletta M., Cagnacci A. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health 2014, 6:745-757.
89. Hoorn E.J., Walsh S.B., McCormick J.A., et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011, 17(10):1304-1309.